PARIS, Jan 11, 2026, 20:53 CET — The market has closed.
- L’Oreal’s stock closed Friday up 6.32% at 385.85 euros, outpacing the CAC 40.
- UBS raised its rating on the stock to Buy and increased the price target to 430 euros.
- Traders are eyeing U.S. inflation figures set for Jan. 13, along with L’Oreal’s annual results due Feb. 12.
L’Oreal (OREP.PA) shares climbed 6.32% on Friday, finishing at 385.85 euros. During the session, the stock fluctuated between 372.80 and 385.85 euros. Approximately 553,000 shares traded hands, based on historical data.
The surge came after UBS made a rare move, upgrading its rating to Buy from Neutral. Analyst Guillaume Delmas also hiked the price target to 430 euros, describing the stock as a “rare combination” of improving momentum and “compelling valuation.”
UBS highlighted quicker demand in both the U.S. and China along with improved market share gains. The bank forecasts like-for-like sales growth of 6.4% in Q4 2025 and 5.8% in 2026, surpassing consensus estimates. By focusing on like-for-like figures, UBS removes distortions from currency fluctuations and acquisitions, offering a clearer picture of core sales trends.
Friday’s session saw a risk-on mood in Paris, pushing the CAC 40 up 1.44% to a fresh record close. Consumer stocks led the broad-based gains, market data showed.
Beyond broker calls, L’Oreal is working through a pipeline of larger, slower-moving catalysts. Back in October, it struck a deal to acquire Kering’s beauty business for 4 billion euros. The package includes the luxury fragrance brand Creed and long-term licenses linked to Kering’s fashion labels. Reuters reported the deal is expected to close in the first half of 2026.
Capital allocation is drawing attention. In December, L’Oreal announced plans to raise its stake in Swiss skincare company Galderma to 20%, with the deal set to close in the first quarter of 2026.
The company secured new funding on Jan. 7 by pricing a 1.75 billion euro triple-tranche bond. It stated the net proceeds would cover general corporate expenses, including part-financing the extra Galderma stake. The notes are set to start trading on Euronext Paris from the settlement date, Jan. 12.
But the risk scenario is straightforward. A one-day squeeze can vanish fast if upcoming data underwhelm, and cosmetics isn’t shielded from a dip in U.S. spending or another slowdown in China. A sudden shift in the euro could also shake up overseas earnings when converted back into euros.
Trading picks up Monday, and macro factors might weigh in. Tuesday, Jan. 13, brings U.S. consumer price data for December—a report that frequently shakes bond yields and, by extension, the value of big consumer stocks.
L’Oreal’s next major company event is set for Feb. 12, when it will release its 2025 annual results after the market closes. A financial information meeting follows the next day, Feb. 13.
